SciClone looks for in-licensing/M&A opportunities in emerging markets
This article was originally published in Scrip
Executive Summary
SciClone Pharmaceuticals is aiming to build on its new emerging markets focus by in-licensing products and/or acquiring whole companies over the coming months, ideally in China where it already has a proven sales infrastructure.